151 related articles for article (PubMed ID: 20107171)
1. Gelatinase expression in retinoblastoma: modulation of LH(BETA)T(AG) retinal tumor development by anecortave acetate.
Bajenaru ML; Piña Y; Murray TG; Cebulla CM; Feuer W; Jockovich ME; Marin Castaño ME
Invest Ophthalmol Vis Sci; 2010 Jun; 51(6):2860-4. PubMed ID: 20107171
[TBL] [Abstract][Full Text] [Related]
2. Anecortave acetate as single and adjuvant therapy in the treatment of retinal tumors of LH(BETA)T(AG) mice.
Jockovich ME; Murray TG; Escalona-Benz E; Hernandez E; Feuer W
Invest Ophthalmol Vis Sci; 2006 Apr; 47(4):1264-8. PubMed ID: 16565356
[TBL] [Abstract][Full Text] [Related]
3. Increased hypoxia following vessel targeting in a murine model of retinoblastoma.
Boutrid H; Piña Y; Cebulla CM; Feuer WJ; Lampidis TJ; Jockovich ME; Murray TG
Invest Ophthalmol Vis Sci; 2009 Dec; 50(12):5537-43. PubMed ID: 19578014
[TBL] [Abstract][Full Text] [Related]
4. Retinoblastoma tumor vessel maturation impacts efficacy of vessel targeting in the LH(BETA)T(AG) mouse model.
Jockovich ME; Bajenaru ML; Piña Y; Suarez F; Feuer W; Fini ME; Murray TG
Invest Ophthalmol Vis Sci; 2007 Jun; 48(6):2476-82. PubMed ID: 17525173
[TBL] [Abstract][Full Text] [Related]
5. Mechanism of retinoblastoma tumor cell death after focal chemotherapy, radiation, and vascular targeting therapy in a mouse model.
Jockovich ME; Suarez F; Alegret A; Piña Y; Hayden B; Cebulla C; Feuer W; Murray TG
Invest Ophthalmol Vis Sci; 2007 Dec; 48(12):5371-6. PubMed ID: 18055783
[TBL] [Abstract][Full Text] [Related]
6. Impact of tumor-associated macrophages in LH(BETA)T(AG) mice on retinal tumor progression: relation to macrophage subtype.
Piña Y; Boutrid H; Murray TG; Jager MJ; Cebulla CM; Schefler A; Ly LV; Alegret A; Celdran M; Feuer W; Jockovich ME
Invest Ophthalmol Vis Sci; 2010 May; 51(5):2671-7. PubMed ID: 20053982
[TBL] [Abstract][Full Text] [Related]
7. Paclitaxel in the treatment of retinal tumors of LH beta-Tag murine transgenic model of retinoblastoma.
Suárez F; Jockovich ME; Hernandez E; Feuer W; Parel JM; Murray TG
Invest Ophthalmol Vis Sci; 2007 Aug; 48(8):3437-40. PubMed ID: 17652710
[TBL] [Abstract][Full Text] [Related]
8. Subconjunctival topotecan in fibrin sealant in the treatment of transgenic murine retinoblastoma.
Tsui JY; Dalgard C; Van Quill KR; Lee L; Grossniklaus HE; Edelhauser HF; O'Brien JM
Invest Ophthalmol Vis Sci; 2008 Feb; 49(2):490-6. PubMed ID: 18234990
[TBL] [Abstract][Full Text] [Related]
9. Blood vessel maturation in retinoblastoma tumors: spatial distribution of neovessels and mature vessels and its impact on ocular treatment.
Piña Y; Boutrid H; Schefler A; Dubovy S; Feuer W; Jockovich ME; Murray TG
Invest Ophthalmol Vis Sci; 2009 Mar; 50(3):1020-4. PubMed ID: 18952925
[TBL] [Abstract][Full Text] [Related]
10. Retinoblastoma treatment: utilization of the glycolytic inhibitor, 2-deoxy-2-fluoro-D-glucose (2-FG), to target the chemoresistant hypoxic regions in LH(BETA)T(AG) retinal tumors.
Piña Y; Decatur C; Murray TG; Houston SK; Lopez-Cavalcante M; Hernandez E; Celdran M; Shah N; Feuer W; Lampidis T
Invest Ophthalmol Vis Sci; 2012 Feb; 53(2):996-1002. PubMed ID: 22266512
[TBL] [Abstract][Full Text] [Related]
11. Subconjunctival carboplatin in fibrin sealant in the treatment of transgenic murine retinoblastoma.
Van Quill KR; Dioguardi PK; Tong CT; Gilbert JA; Aaberg TM; Grossniklaus HE; Edelhauser HF; O'Brien JM
Ophthalmology; 2005 Jun; 112(6):1151-8. PubMed ID: 15885791
[TBL] [Abstract][Full Text] [Related]
12. Subconjunctival carboplatin in retinoblastoma: impact of tumor burden and dose schedule.
Hayden BH; Murray TG; Scott IU; Cicciarelli N; Hernandez E; Feuer W; Fulton L; O'Brien JM
Arch Ophthalmol; 2000 Nov; 118(11):1549-54. PubMed ID: 11074812
[TBL] [Abstract][Full Text] [Related]
13. Targeting hypoxia, a novel treatment for advanced retinoblastoma.
Boutrid H; Jockovich ME; Murray TG; Piña Y; Feuer WJ; Lampidis TJ; Cebulla CM
Invest Ophthalmol Vis Sci; 2008 Jul; 49(7):2799-805. PubMed ID: 18326690
[TBL] [Abstract][Full Text] [Related]
14. [Aging changes of gelatinase activity in kidney tissue of autoimmune MRL/lpr mice].
Cai G; Chen X; Wang Z; Tian Y; Shi S
Zhonghua Bing Li Xue Za Zhi; 2002 Oct; 31(5):432-5. PubMed ID: 12485487
[TBL] [Abstract][Full Text] [Related]
15. Focal, periocular delivery of 2-deoxy-D-glucose as adjuvant to chemotherapy for treatment of advanced retinoblastoma.
Piña Y; Houston SK; Murray TG; Boutrid H; Celdran M; Feuer W; Shi W; Hernandez E; Lampidis TJ
Invest Ophthalmol Vis Sci; 2010 Dec; 51(12):6149-56. PubMed ID: 20702830
[TBL] [Abstract][Full Text] [Related]
16. Differential roles of matrix metalloproteinase-9 and -2, depending on proliferation or differentiation of retinoblastoma cells.
Kim JH; Kim JH; Cho CS; Jun HO; Kim DH; Yu YS; Kim KW
Invest Ophthalmol Vis Sci; 2010 Mar; 51(3):1783-8. PubMed ID: 19933182
[TBL] [Abstract][Full Text] [Related]
17. Implication of gelatinases in retinoblastoma development.
Zamfir-Chiru-Anton A; Gheorghe Dan C
Rom J Ophthalmol; 2016; 60(2):68-70. PubMed ID: 29450326
[TBL] [Abstract][Full Text] [Related]
18. Vitamin D analogs, a new treatment for retinoblastoma: The first Ellsworth Lecture.
Albert DM; Nickells RW; Gamm DM; Zimbric ML; Schlamp CL; Lindstrom MJ; Audo I
Ophthalmic Genet; 2002 Sep; 23(3):137-56. PubMed ID: 12324873
[TBL] [Abstract][Full Text] [Related]
19. Novel retinoblastoma treatment avoids chemotherapy: the effect of optimally timed combination therapy with angiogenic and glycolytic inhibitors on LH(BETA)T(AG) retinoblastoma tumors.
Houston SK; Piña Y; Murray TG; Boutrid H; Cebulla C; Schefler AC; Shi W; Celdran M; Feuer W; Merchan J; Lampidis TJ
Clin Ophthalmol; 2011 Jan; 5():129-37. PubMed ID: 21339806
[TBL] [Abstract][Full Text] [Related]
20. The experiment research of subconjunctival injections with etoposide for the treatment of retinoblastoma mice.
Mao Y; Zhongyao W; Huasheng Y; Zheng J; He J; Li W
Yan Ke Xue Bao; 2005 Sep; 21(3):169-74. PubMed ID: 17162856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
